New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:40 EDTRL, AZNOptions with increasing implied volatility: RL AZN
News For RL;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
11:51 EDTAZNExpress Scripts' Medco to pay $7.9M to resolve kickback allegations
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
May 19, 2015
15:05 EDTAZNArdelyx scheduled for end Phase 2 meeting with FDA scheduled in June
Subscribe for More Information
May 18, 2015
06:13 EDTAZNAstraZeneca to invest $285M in new biologics manufacturing facility in Sweden
AstraZeneca announced that it plans to invest approximately $285M in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical trial programs of AstraZeneca and MedImmune, the company’s global biologics research and development arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019. Södertälje is currently home to AstraZeneca’s largest global tablets and capsules manufacturing facility and is also a launch platform site for the company, with specialist capabilities on-site that allow large-scale production of new medicines, working closely with the research and development organisation. By locating the new manufacturing plant in Södertälje, the company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit. The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019. The new manufacturing facility in Sweden will support the progression of drug candidates across the main therapy areas and be aligned with investments being made in the current biologics manufacturing centers, such as the expansion in Frederick, Maryland, announced in November.
May 17, 2015
15:49 EDTAZNAstraZeneca reports Movantik shows 'similar' adverse event rate vs. placebo
Subscribe for More Information
13:59 EDTRLRalph Lauren shares could return 15%-20% in 12-18 months, Barron's says
Subscribe for More Information
May 15, 2015
10:20 EDTRLOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
09:31 EDTAZNAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
09:22 EDTAZNLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:41 EDTRLUSPA gets favorable ruling in trademark fight with Ralph Lauren, Reuters says
Subscribe for More Information
05:52 EDTAZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
09:21 EDTRLOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTRLRalph Lauren sees forex, global consumer spending remaining 'unpredictable'
Subscribe for More Information
08:07 EDTRLRalph Lauren seesn Q1 consolidated net revenues flat in constant currency
In the first quarter of Fiscal 2016, the Company expects consolidated net revenues to be flat in constant currency, as retail segment growth is offset by a decline in wholesale revenue which is impacted by our customers’ receipt plans due to an earlier Easter this year. Based on current exchange rates, foreign currency will have an approximate 600 basis point negative impact on revenue growth in the first quarter of Fiscal 2016. Operating margin for the first quarter of Fiscal 2016 is expected to be approximately 600-650 basis points below the comparable prior year period, primarily due to negative foreign currency effects, the quarterly revenue growth profile and timing of expense savings initiatives. The first quarter tax rate is estimated at 30%.
08:06 EDTRLRalph Lauren sees FY15 consolidated net revenue up mid single digits
The company currently expects consolidated net revenues for Fiscal 2016 to increase by mid-single digits in constant currency. The company says, "Based on current exchange rates, foreign currency will have an approximate 450 basis point negative impact on Fiscal 2016 revenue growth. Operating margin for Fiscal 2016 is currently expected to be 180-230 basis points below the prior year’s level due to negative foreign currency effects. The full year Fiscal 2016 tax rate is estimated at 30%. Capital expenditures are planned at approximately $400-$500 million in Fiscal 2016. This guidance excludes restructuring and other one-time related charges associated with our global brand reorganization. We expect these charges to be approximately $70-100 million over the course of Fiscal 2016."
08:06 EDTRLRalph Lauren board authorizes additional $500M stock repurchase program
Subscribe for More Information
08:05 EDTRLRalph Lauren reports Q4 EPS $1.69 ex-foreign currency impacts, consensus $1.32
Subscribe for More Information
May 12, 2015
15:00 EDTRLNotable companies reporting before tomorrow's open
Subscribe for More Information
14:11 EDTRLRalph Lauren technical comments before earnings
The shares have been in decline for the prior year, but ahead of earnings have entered a consolidation phase. That range is largely contained within the bounds of $130 to $140. Those two extremes of the range can help us understand where price may go following earnings. A breakout above $140 on better than expected news would turn the dominant downtrend to neutral. A rise above $149.16 would set the trend to bullish in the short-term, with next resistance at $153.27. That level is the bottom of the bearish gap down from February. A move further up into the gap would be bullish. If the news is bearish and the low of the range at $130 is taken out on the downside, it would signal a resumption of the downtrend. In that event next support would be at $127.29, which is the 52-week low. A breakdown below the 52-week low could see the following support levels become potential downside objectives depending on the degree of negative surprise: $122.98, $117.29, and $111.65.
May 8, 2015
11:18 EDTRLRalph Lauren May volatility elevated into Q4 and outlook
Ralph Lauren May call option implied volatility is at 52, June is at 29, October is at 26; compared to its 90-week average of 27, suggesting large near term price movement into the expected release of Q4 results on May 13.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use